Suvorexant for sleep-onset insomnia or sleep-maintenance insomnia, or both

David Neubauer

Suvorexant for sleep-onset insomnia or sleep-maintenance insomnia, or both

David Neubauer

School of Medicine

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

Suvorexant, FDA-approved to treat insomnia, has demonstrated efficacy in helping patients with insomnia improve their ability to fall asleep and remain asleep (Table 1).¹ This first-in-class compound represents a novel mechanism of action to promoting sleep that may avoid some problems associated with other hypnotics.².

Original language	English (US)
Pages (from-to)	19-24
Number of pages	6
Journal	Current Psychiatry
Volume	14
Issue number	1
State	Published - 2015

ASJC Scopus subject areas

Psychiatry and Mental health

Cite this

@article{c7428911e3cf45e0ad499122ae07f2af,

title = "Suvorexant for sleep-onset insomnia or sleep-maintenance insomnia, or both",

abstract = "Suvorexant, FDA-approved to treat insomnia, has demonstrated efficacy in helping patients with insomnia improve their ability to fall asleep and remain asleep (Table 1).1 This first-in-class compound represents a novel mechanism of action to promoting sleep that may avoid some problems associated with other hypnotics.2.",

author = "David Neubauer",

year = "2015",

language = "English (US)",

volume = "14",

pages = "19--24",

journal = "Current Psychiatry",

issn = "1537-8276",

publisher = "Dowden Health Media,Inc",

number = "1",

}

TY - JOUR

T1 - Suvorexant for sleep-onset insomnia or sleep-maintenance insomnia, or both

AU - Neubauer, David

PY - 2015

Y1 - 2015

N2 - Suvorexant, FDA-approved to treat insomnia, has demonstrated efficacy in helping patients with insomnia improve their ability to fall asleep and remain asleep (Table 1).1 This first-in-class compound represents a novel mechanism of action to promoting sleep that may avoid some problems associated with other hypnotics.2.

AB - Suvorexant, FDA-approved to treat insomnia, has demonstrated efficacy in helping patients with insomnia improve their ability to fall asleep and remain asleep (Table 1).1 This first-in-class compound represents a novel mechanism of action to promoting sleep that may avoid some problems associated with other hypnotics.2.

UR - http://www.scopus.com/inward/record.url?scp=84922164435&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84922164435&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84922164435

SN - 1537-8276

VL - 14

SP - 19

EP - 24

JO - Current Psychiatry

JF - Current Psychiatry

IS - 1

ER -

Suvorexant for sleep-onset insomnia or sleep-maintenance insomnia, or both

Abstract

ASJC Scopus subject areas

Other files and links

Fingerprint

Cite this